ResMed Targets Drop to $225 at Wells Fargo; Upside Remains at +23.2%
Key Takeaways
- Wells Fargo’s $225 target is the lowest among major banks, yet ResMed’s average analyst target of $270.64 implies a 23.2% upside.
- Markets weigh defensive balance sheet qualities against emerging therapeutic competition.
Mentioned
Key Intelligence
Key Facts
- 1Wells Fargo reduced ResMed price target from $227 to $225, keeping an Equal Weight rating, implying 2.45% upside from prior close.
- 2Consensus analyst rating stands at Moderate Buy with an average price target of $270.64, based on 1 Strong Buy, 9 Buys, and 6 Holds.
- 3Morgan Stanley cut its target to $230 (from $286) and Citigroup to $270 (from $340) in June, reflecting significant downward revisions.
- 4ResMed shares opened at $219.62 on July 8, 2026, with a 50-day moving average of $201.12 and 200-day moving average of $228.95.
- 5The company has a market cap of $31.86B, P/E of 21.18, PEG of 1.28, debt-to-equity of 0.06, and a beta of 0.78.
- 6Royal Bank of Canada raised its target to $321 in May, maintaining an Outperform rating, highlighting the wide dispersion in analyst outlooks.
Average target implies substantial upside based on 16 analysts
Analysis
- Consensus target 23.2% above current price
- Debt-to-equity of just 0.06 and high liquidity
- PEG ratio of 1.28 suggests reasonable growth value
- Series of analyst target cuts erode confidence
- GLP-1 drugs threaten long-term sleep apnea volumes
- Stock trades below 200-day moving average of $228.95
Analysis
With a P/E of 21.18 and virtually no debt, ResMed seems like a value play in a volatile market. But the recent wave of target cuts—especially from giants like Morgan Stanley and Citigroup—suggests that even fortress-like financials cannot fully insulate the stock from sectoral disruption by pharmaceutical breakthroughs.
Wells Fargo & Company lowered its price target on ResMed (NYSE:RMD) to $225.00 from $227.00 while maintaining an 'equal weight' rating, signaling a cautious stance on the medical device leader that sits at the heart of the sleep apnea and respiratory care market. The modest $2 cut, reported July 8, 2026, comes amid a broader recalibration of analyst expectations for ResMed, with multiple Wall Street firms slashing targets over the past two months—Morgan Stanley to $230 from $286, Citigroup to $270 from $340—while others like Royal Bank of Canada raised theirs to $321. The result is a highly divided analyst community: 10 Buy or Strong Buy ratings against 6 Holds, producing an average consensus target of $270.64, which implies a 23% upside from the $219.62 opening price on Wednesday.
The stock’s 50-day moving average of $201.12 has trended upward recently, hinting at short-term recovery, but it remains well below the 200-day average of $228.95 and far from its 12-month high of $293.81.
This polarization reflects uncertainty about ResMed’s growth trajectory. Historically, the company benefited enormously from a competitor’s massive CPAP recall (Philips) that drove market share gains and boosted revenues. However, that tailwind is maturing. A new threat looms in the form of GLP-1 weight loss drugs such as semaglutide, which could meaningfully shrink the addressable pool of sleep apnea patients if obesity—a major risk factor—is treated pharmacologically. Studies on tirzepatide’s efficacy in obstructive sleep apnea have already stirred debate, and while ResMed management points to low therapy penetration rates globally as a cushion, the market is pricing in a potential demand slowdown. The stock’s 50-day moving average of $201.12 has trended upward recently, hinting at short-term recovery, but it remains well below the 200-day average of $228.95 and far from its 12-month high of $293.81.
What to Watch
ResMed’s financials remain robust: a market cap of $31.86 billion, P/E ratio of 21.18, negligible debt-to-equity of 0.06, and solid liquidity metrics (current ratio 3.01, quick ratio 2.33). The company last reported earnings on April 30, 2026, and while details from that report are not contained in these analyst notes, the subsequent wave of target cuts suggests that forward guidance or secular headwinds disappointed. The 1.28 PEG ratio indicates expectations of moderate growth, but the beta of 0.78 implies the stock is less volatile than the broader market, making it an interesting defensive play within healthcare if the device cycle proves resilient.
For investors, the divergent views underscore the importance of monitoring upcoming clinical data on GLP-1s in sleep apnea and any ResMed-specific catalysts—new product launches, market expansion in emerging economies, or digital health integrations—that could re-rate the stock. The Wells Fargo target, while low, still offers a slim 2.45% upside, reflecting an expectation that the stock already prices in many risks. The deeper question is whether the consensus $270.64 target is too optimistic or the pessimistic targets are overly conservative. The answer will hinge on how quickly the obesity-drug narrative materializes into actual CPAP prescription declines.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |